nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—lung cancer—thyroid cancer	0.347	1	CtDrD
Crizotinib—RIPK2—Vandetanib—thyroid cancer	0.0226	0.0471	CbGbCtD
Crizotinib—MUSK—Sorafenib—thyroid cancer	0.0189	0.0393	CbGbCtD
Crizotinib—CDK7—Sorafenib—thyroid cancer	0.0189	0.0393	CbGbCtD
Crizotinib—EPHA5—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—STK35—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—AXL—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—BMPR1B—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—TYRO3—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—LTK—Vandetanib—thyroid cancer	0.018	0.0374	CbGbCtD
Crizotinib—AURKA—Epirubicin—thyroid cancer	0.0156	0.0324	CbGbCtD
Crizotinib—PLK4—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—YES1—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—TEK—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—SLK—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—MAP4K5—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—EPHA8—Vandetanib—thyroid cancer	0.015	0.0313	CbGbCtD
Crizotinib—TIE1—Sorafenib—thyroid cancer	0.0136	0.0284	CbGbCtD
Crizotinib—TAOK2—Sorafenib—thyroid cancer	0.0136	0.0284	CbGbCtD
Crizotinib—FLT3—Vandetanib—thyroid cancer	0.013	0.0271	CbGbCtD
Crizotinib—FGR—Vandetanib—thyroid cancer	0.013	0.0271	CbGbCtD
Crizotinib—BLK—Vandetanib—thyroid cancer	0.0115	0.0239	CbGbCtD
Crizotinib—EPHB6—Vandetanib—thyroid cancer	0.0115	0.0239	CbGbCtD
Crizotinib—EPHA6—Vandetanib—thyroid cancer	0.0115	0.0239	CbGbCtD
Crizotinib—SRC—Vandetanib—thyroid cancer	0.0115	0.0239	CbGbCtD
Crizotinib—LYN—Vandetanib—thyroid cancer	0.0115	0.0239	CbGbCtD
Crizotinib—ABL2—Vandetanib—thyroid cancer	0.0103	0.0215	CbGbCtD
Crizotinib—STK10—Vandetanib—thyroid cancer	0.0103	0.0215	CbGbCtD
Crizotinib—LCK—Vandetanib—thyroid cancer	0.0094	0.0196	CbGbCtD
Crizotinib—MAP3K19—Vandetanib—thyroid cancer	0.00864	0.018	CbGbCtD
Crizotinib—AURKA—Doxorubicin—thyroid cancer	0.00827	0.0172	CbGbCtD
Crizotinib—FLT3—Sorafenib—thyroid cancer	0.00783	0.0163	CbGbCtD
Crizotinib—ABL1—Vandetanib—thyroid cancer	0.00746	0.0155	CbGbCtD
Crizotinib—EPHA6—Sorafenib—thyroid cancer	0.00692	0.0144	CbGbCtD
Crizotinib—EPHB6—Sorafenib—thyroid cancer	0.00692	0.0144	CbGbCtD
Crizotinib—STK10—Sorafenib—thyroid cancer	0.00622	0.013	CbGbCtD
Crizotinib—CSF1R—Sorafenib—thyroid cancer	0.00622	0.013	CbGbCtD
Crizotinib—MAP3K19—Sorafenib—thyroid cancer	0.00521	0.0108	CbGbCtD
Crizotinib—Drug-induced liver injury—Sorafenib—thyroid cancer	0.00356	0.0697	CcSEcCtD
Crizotinib—Electrocardiogram QT corrected interval prolonged—Vandetanib—thyroid cancer	0.00205	0.0403	CcSEcCtD
Crizotinib—Photopsia—Vandetanib—thyroid cancer	0.00174	0.0341	CcSEcCtD
Crizotinib—Disease progression—Sorafenib—thyroid cancer	0.00171	0.0335	CcSEcCtD
Crizotinib—Gastrointestinal perforation—Sorafenib—thyroid cancer	0.00143	0.028	CcSEcCtD
Crizotinib—Peripheral sensory neuropathy—Sorafenib—thyroid cancer	0.00131	0.0256	CcSEcCtD
Crizotinib—Dysaesthesia—Vandetanib—thyroid cancer	0.00128	0.0251	CcSEcCtD
Crizotinib—Balance disorder—Vandetanib—thyroid cancer	0.00101	0.0198	CcSEcCtD
Crizotinib—Visual acuity reduced—Vandetanib—thyroid cancer	0.00093	0.0182	CcSEcCtD
Crizotinib—Electrocardiogram QT prolonged—Vandetanib—thyroid cancer	0.000862	0.0169	CcSEcCtD
Crizotinib—SBK3—thyroid gland—thyroid cancer	0.000862	0.0182	CbGeAlD
Crizotinib—Haemoglobin decreased—Vandetanib—thyroid cancer	0.000804	0.0158	CcSEcCtD
Crizotinib—Interstitial lung disease—Vandetanib—thyroid cancer	0.000782	0.0153	CcSEcCtD
Crizotinib—Lymphopenia—Sorafenib—thyroid cancer	0.000729	0.0143	CcSEcCtD
Crizotinib—Hypophosphataemia—Sorafenib—thyroid cancer	0.000642	0.0126	CcSEcCtD
Crizotinib—MET—neck—thyroid cancer	0.000607	0.0128	CbGeAlD
Crizotinib—CYP3A5—Sorafenib—thyroid cancer	0.000569	0.00119	CbGbCtD
Crizotinib—Respiratory failure—Vandetanib—thyroid cancer	0.000563	0.011	CcSEcCtD
Crizotinib—Haemoglobin decreased—Sorafenib—thyroid cancer	0.000542	0.0106	CcSEcCtD
Crizotinib—IKBKE—thyroid gland—thyroid cancer	0.000532	0.0112	CbGeAlD
Crizotinib—Interstitial lung disease—Sorafenib—thyroid cancer	0.000527	0.0103	CcSEcCtD
Crizotinib—FES—saliva-secreting gland—thyroid cancer	0.000501	0.0106	CbGeAlD
Crizotinib—Peripheral sensory neuropathy—Epirubicin—thyroid cancer	0.000483	0.00946	CcSEcCtD
Crizotinib—Sepsis—Vandetanib—thyroid cancer	0.00048	0.00941	CcSEcCtD
Crizotinib—IGF1R—neck—thyroid cancer	0.000477	0.0101	CbGeAlD
Crizotinib—ANKK1—head—thyroid cancer	0.000472	0.00996	CbGeAlD
Crizotinib—Peripheral sensory neuropathy—Doxorubicin—thyroid cancer	0.000447	0.00875	CcSEcCtD
Crizotinib—Polyneuropathy—Epirubicin—thyroid cancer	0.000423	0.00829	CcSEcCtD
Crizotinib—BMP2K—neck—thyroid cancer	0.000398	0.0084	CbGeAlD
Crizotinib—Polyneuropathy—Doxorubicin—thyroid cancer	0.000392	0.00767	CcSEcCtD
Crizotinib—ABCB1—Sorafenib—thyroid cancer	0.00037	0.000771	CbGbCtD
Crizotinib—CYP3A4—Vandetanib—thyroid cancer	0.000368	0.000767	CbGbCtD
Crizotinib—Hypokalaemia—Vandetanib—thyroid cancer	0.000365	0.00716	CcSEcCtD
Crizotinib—PTK2—neck—thyroid cancer	0.000354	0.00747	CbGeAlD
Crizotinib—TBK1—neck—thyroid cancer	0.000354	0.00747	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.000354	0.00694	CcSEcCtD
Crizotinib—Neuropathy—Sorafenib—thyroid cancer	0.00035	0.00687	CcSEcCtD
Crizotinib—TESK1—saliva-secreting gland—thyroid cancer	0.00035	0.00738	CbGeAlD
Crizotinib—PRKD1—thyroid gland—thyroid cancer	0.000348	0.00733	CbGeAlD
Crizotinib—LIMK1—thyroid gland—thyroid cancer	0.000343	0.00723	CbGeAlD
Crizotinib—RPS6KB1—neck—thyroid cancer	0.000341	0.00719	CbGeAlD
Crizotinib—NEK9—head—thyroid cancer	0.000338	0.00714	CbGeAlD
Crizotinib—PRKD3—thyroid gland—thyroid cancer	0.000334	0.00705	CbGeAlD
Crizotinib—NUAK2—saliva-secreting gland—thyroid cancer	0.000332	0.007	CbGeAlD
Crizotinib—IKBKE—lymph node—thyroid cancer	0.000331	0.00697	CbGeAlD
Crizotinib—ACVR1—saliva-secreting gland—thyroid cancer	0.000329	0.00695	CbGeAlD
Crizotinib—DSTYK—thyroid gland—thyroid cancer	0.000326	0.00688	CbGeAlD
Crizotinib—Neutropenia—Vandetanib—thyroid cancer	0.000325	0.00636	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.000323	0.00632	CcSEcCtD
Crizotinib—DCLK1—trachea—thyroid cancer	0.00032	0.00675	CbGeAlD
Crizotinib—Dysaesthesia—Epirubicin—thyroid cancer	0.000319	0.00625	CcSEcCtD
Crizotinib—CASK—thyroid gland—thyroid cancer	0.000319	0.00673	CbGeAlD
Crizotinib—Weight decreased—Vandetanib—thyroid cancer	0.000314	0.00615	CcSEcCtD
Crizotinib—Pneumonia—Vandetanib—thyroid cancer	0.000311	0.0061	CcSEcCtD
Crizotinib—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00031	0.00607	CcSEcCtD
Crizotinib—Infestation—Vandetanib—thyroid cancer	0.000309	0.00607	CcSEcCtD
Crizotinib—Infestation NOS—Vandetanib—thyroid cancer	0.000309	0.00607	CcSEcCtD
Crizotinib—MAPK7—thyroid gland—thyroid cancer	0.000309	0.00651	CbGeAlD
Crizotinib—PRKD1—head—thyroid cancer	0.000308	0.00651	CbGeAlD
Crizotinib—FES—thyroid gland—thyroid cancer	0.000306	0.00645	CbGeAlD
Crizotinib—SIK2—head—thyroid cancer	0.000304	0.00642	CbGeAlD
Crizotinib—Hepatic failure—Sorafenib—thyroid cancer	0.000301	0.00591	CcSEcCtD
Crizotinib—FER—trachea—thyroid cancer	0.000299	0.0063	CbGeAlD
Crizotinib—RIPK2—saliva-secreting gland—thyroid cancer	0.000298	0.00628	CbGeAlD
Crizotinib—TNK1—trachea—thyroid cancer	0.000296	0.00624	CbGeAlD
Crizotinib—Dysaesthesia—Doxorubicin—thyroid cancer	0.000295	0.00578	CcSEcCtD
Crizotinib—Hepatobiliary disease—Vandetanib—thyroid cancer	0.000293	0.00574	CcSEcCtD
Crizotinib—MET—thyroid gland—thyroid cancer	0.000289	0.0061	CbGeAlD
Crizotinib—LTK—head—thyroid cancer	0.000283	0.00597	CbGeAlD
Crizotinib—Bradycardia—Vandetanib—thyroid cancer	0.000283	0.00554	CcSEcCtD
Crizotinib—CDK7—thyroid gland—thyroid cancer	0.00028	0.0059	CbGeAlD
Crizotinib—TAOK2—thyroid gland—thyroid cancer	0.000277	0.00585	CbGeAlD
Crizotinib—TBK1—saliva-secreting gland—thyroid cancer	0.000276	0.00583	CbGeAlD
Crizotinib—PTK2—saliva-secreting gland—thyroid cancer	0.000276	0.00583	CbGeAlD
Crizotinib—TYK2—saliva-secreting gland—thyroid cancer	0.000274	0.00579	CbGeAlD
Crizotinib—Urinary tract disorder—Vandetanib—thyroid cancer	0.000274	0.00538	CcSEcCtD
Crizotinib—MAPK7—head—thyroid cancer	0.000274	0.00578	CbGeAlD
Crizotinib—TXK—head—thyroid cancer	0.000274	0.00578	CbGeAlD
Crizotinib—Urethral disorder—Vandetanib—thyroid cancer	0.000272	0.00534	CcSEcCtD
Crizotinib—EPHA8—head—thyroid cancer	0.000271	0.00572	CbGeAlD
Crizotinib—TESK1—trachea—thyroid cancer	0.00027	0.0057	CbGeAlD
Crizotinib—Lymphopenia—Epirubicin—thyroid cancer	0.00027	0.00528	CcSEcCtD
Crizotinib—Visual impairment—Vandetanib—thyroid cancer	0.000268	0.00525	CcSEcCtD
Crizotinib—ACVR1B—thyroid gland—thyroid cancer	0.000267	0.00564	CbGeAlD
Crizotinib—EPHA3—thyroid gland—thyroid cancer	0.000267	0.00564	CbGeAlD
Crizotinib—RPS6KB1—saliva-secreting gland—thyroid cancer	0.000266	0.00561	CbGeAlD
Crizotinib—Eye disorder—Vandetanib—thyroid cancer	0.00026	0.00509	CcSEcCtD
Crizotinib—Cardiac disorder—Vandetanib—thyroid cancer	0.000258	0.00505	CcSEcCtD
Crizotinib—LIMK2—trachea—thyroid cancer	0.000257	0.00542	CbGeAlD
Crizotinib—MET—head—thyroid cancer	0.000256	0.00541	CbGeAlD
Crizotinib—NUAK2—trachea—thyroid cancer	0.000256	0.0054	CbGeAlD
Crizotinib—JAK3—thyroid gland—thyroid cancer	0.000255	0.00538	CbGeAlD
Crizotinib—ACVR1—trachea—thyroid cancer	0.000254	0.00536	CbGeAlD
Crizotinib—SLK—saliva-secreting gland—thyroid cancer	0.000253	0.00534	CbGeAlD
Crizotinib—DCLK1—thyroid gland—thyroid cancer	0.000253	0.00534	CbGeAlD
Crizotinib—EPHB4—saliva-secreting gland—thyroid cancer	0.000251	0.0053	CbGeAlD
Crizotinib—Mediastinal disorder—Vandetanib—thyroid cancer	0.00025	0.00491	CcSEcCtD
Crizotinib—STK4—thyroid gland—thyroid cancer	0.00025	0.00528	CbGeAlD
Crizotinib—Lymphopenia—Doxorubicin—thyroid cancer	0.000249	0.00489	CcSEcCtD
Crizotinib—Arrhythmia—Vandetanib—thyroid cancer	0.000248	0.00486	CcSEcCtD
Crizotinib—CDK7—head—thyroid cancer	0.000248	0.00523	CbGeAlD
Crizotinib—EPHA2—saliva-secreting gland—thyroid cancer	0.000247	0.0052	CbGeAlD
Crizotinib—Hypokalaemia—Sorafenib—thyroid cancer	0.000247	0.00483	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.000244	0.00478	CcSEcCtD
Crizotinib—Malnutrition—Vandetanib—thyroid cancer	0.000242	0.00474	CcSEcCtD
Crizotinib—MAP4K5—saliva-secreting gland—thyroid cancer	0.000241	0.00508	CbGeAlD
Crizotinib—MAP3K3—saliva-secreting gland—thyroid cancer	0.000241	0.00508	CbGeAlD
Crizotinib—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.000239	0.00468	CcSEcCtD
Crizotinib—Hypophosphataemia—Epirubicin—thyroid cancer	0.000237	0.00465	CcSEcCtD
Crizotinib—ACVR1B—head—thyroid cancer	0.000237	0.005	CbGeAlD
Crizotinib—EPHA3—head—thyroid cancer	0.000237	0.005	CbGeAlD
Crizotinib—NEK9—lymph node—thyroid cancer	0.000237	0.005	CbGeAlD
Crizotinib—Dysgeusia—Vandetanib—thyroid cancer	0.000237	0.00464	CcSEcCtD
Crizotinib—FER—thyroid gland—thyroid cancer	0.000236	0.00499	CbGeAlD
Crizotinib—TNK1—thyroid gland—thyroid cancer	0.000234	0.00494	CbGeAlD
Crizotinib—Generalised oedema—Epirubicin—thyroid cancer	0.000232	0.00454	CcSEcCtD
Crizotinib—BMPR1B—thyroid gland—thyroid cancer	0.000232	0.00489	CbGeAlD
Crizotinib—MAP4K1—thyroid gland—thyroid cancer	0.000232	0.00489	CbGeAlD
Crizotinib—EPHB6—saliva-secreting gland—thyroid cancer	0.00023	0.00485	CbGeAlD
Crizotinib—RIPK2—trachea—thyroid cancer	0.00023	0.00484	CbGeAlD
Crizotinib—Febrile neutropenia—Epirubicin—thyroid cancer	0.000229	0.00449	CcSEcCtD
Crizotinib—Vision blurred—Vandetanib—thyroid cancer	0.000228	0.00447	CcSEcCtD
Crizotinib—IGF1R—thyroid gland—thyroid cancer	0.000227	0.00479	CbGeAlD
Crizotinib—TNK2—thyroid gland—thyroid cancer	0.000227	0.00479	CbGeAlD
Crizotinib—Transaminases increased—Epirubicin—thyroid cancer	0.000227	0.00444	CcSEcCtD
Crizotinib—EPHA6—head—thyroid cancer	0.000226	0.00477	CbGeAlD
Crizotinib—JAK3—head—thyroid cancer	0.000226	0.00477	CbGeAlD
Crizotinib—ABCB1—Doxorubicin—thyroid cancer	0.000225	0.000468	CbGbCtD
Crizotinib—DCLK1—head—thyroid cancer	0.000225	0.00474	CbGeAlD
Crizotinib—MAP4K2—thyroid gland—thyroid cancer	0.000224	0.00473	CbGeAlD
Crizotinib—YES1—saliva-secreting gland—thyroid cancer	0.000222	0.00469	CbGeAlD
Crizotinib—CYP3A4—Sorafenib—thyroid cancer	0.000222	0.000462	CbGbCtD
Crizotinib—STK4—head—thyroid cancer	0.000222	0.00468	CbGeAlD
Crizotinib—EPHA4—trachea—thyroid cancer	0.000222	0.00468	CbGeAlD
Crizotinib—STK3—thyroid gland—thyroid cancer	0.000221	0.00466	CbGeAlD
Crizotinib—TIE1—thyroid gland—thyroid cancer	0.000221	0.00466	CbGeAlD
Crizotinib—Hypophosphataemia—Doxorubicin—thyroid cancer	0.00022	0.0043	CcSEcCtD
Crizotinib—TAOK3—saliva-secreting gland—thyroid cancer	0.000219	0.00463	CbGeAlD
Crizotinib—Neutropenia—Sorafenib—thyroid cancer	0.000219	0.00429	CcSEcCtD
Crizotinib—PRKD1—lymph node—thyroid cancer	0.000216	0.00456	CbGeAlD
Crizotinib—AURKA—thyroid gland—thyroid cancer	0.000215	0.00454	CbGeAlD
Crizotinib—Generalised oedema—Doxorubicin—thyroid cancer	0.000215	0.0042	CcSEcCtD
Crizotinib—TESK1—thyroid gland—thyroid cancer	0.000214	0.00451	CbGeAlD
Crizotinib—TBK1—trachea—thyroid cancer	0.000213	0.0045	CbGeAlD
Crizotinib—PTK2—trachea—thyroid cancer	0.000213	0.0045	CbGeAlD
Crizotinib—LIMK1—lymph node—thyroid cancer	0.000213	0.00449	CbGeAlD
Crizotinib—Loss of consciousness—Vandetanib—thyroid cancer	0.000213	0.00417	CcSEcCtD
Crizotinib—Febrile neutropenia—Doxorubicin—thyroid cancer	0.000212	0.00416	CcSEcCtD
Crizotinib—Weight decreased—Sorafenib—thyroid cancer	0.000212	0.00415	CcSEcCtD
Crizotinib—TYK2—trachea—thyroid cancer	0.000212	0.00447	CbGeAlD
Crizotinib—Pneumonia—Sorafenib—thyroid cancer	0.00021	0.00412	CcSEcCtD
Crizotinib—FER—head—thyroid cancer	0.00021	0.00442	CbGeAlD
Crizotinib—TYRO3—head—thyroid cancer	0.00021	0.00442	CbGeAlD
Crizotinib—EPHA5—head—thyroid cancer	0.00021	0.00442	CbGeAlD
Crizotinib—ALK—head—thyroid cancer	0.00021	0.00442	CbGeAlD
Crizotinib—Transaminases increased—Doxorubicin—thyroid cancer	0.00021	0.00411	CcSEcCtD
Crizotinib—Infestation NOS—Sorafenib—thyroid cancer	0.000209	0.00409	CcSEcCtD
Crizotinib—Infestation—Sorafenib—thyroid cancer	0.000209	0.00409	CcSEcCtD
Crizotinib—LYN—head—thyroid cancer	0.000209	0.0044	CbGeAlD
Crizotinib—MERTK—thyroid gland—thyroid cancer	0.000208	0.00438	CbGeAlD
Crizotinib—PRKD3—lymph node—thyroid cancer	0.000208	0.00438	CbGeAlD
Crizotinib—BMPR1B—head—thyroid cancer	0.000206	0.00433	CbGeAlD
Crizotinib—MAP3K19—head—thyroid cancer	0.000206	0.00433	CbGeAlD
Crizotinib—RPS6KB1—trachea—thyroid cancer	0.000205	0.00433	CbGeAlD
Crizotinib—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000205	0.00401	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000204	0.00401	CcSEcCtD
Crizotinib—LCK—trachea—thyroid cancer	0.000204	0.0043	CbGeAlD
Crizotinib—LIMK2—thyroid gland—thyroid cancer	0.000203	0.00429	CbGeAlD
Crizotinib—AXL—trachea—thyroid cancer	0.000203	0.00428	CbGeAlD
Crizotinib—DSTYK—lymph node—thyroid cancer	0.000203	0.00427	CbGeAlD
Crizotinib—NUAK2—thyroid gland—thyroid cancer	0.000202	0.00427	CbGeAlD
Crizotinib—IGF1R—head—thyroid cancer	0.000202	0.00425	CbGeAlD
Crizotinib—TNK2—head—thyroid cancer	0.000202	0.00425	CbGeAlD
Crizotinib—MAP3K12—thyroid gland—thyroid cancer	0.000201	0.00424	CbGeAlD
Crizotinib—ACVR1—thyroid gland—thyroid cancer	0.000201	0.00424	CbGeAlD
Crizotinib—BLK—lymph node—thyroid cancer	0.0002	0.00423	CbGeAlD
Crizotinib—Burning sensation—Epirubicin—thyroid cancer	0.000199	0.00389	CcSEcCtD
Crizotinib—Neuralgia—Epirubicin—thyroid cancer	0.000199	0.00389	CcSEcCtD
Crizotinib—LTK—lymph node—thyroid cancer	0.000198	0.00418	CbGeAlD
Crizotinib—CASK—lymph node—thyroid cancer	0.000198	0.00418	CbGeAlD
Crizotinib—Hepatobiliary disease—Sorafenib—thyroid cancer	0.000197	0.00387	CcSEcCtD
Crizotinib—Oedema—Vandetanib—thyroid cancer	0.000197	0.00387	CcSEcCtD
Crizotinib—STK35—thyroid gland—thyroid cancer	0.000197	0.00415	CbGeAlD
Crizotinib—Infection—Vandetanib—thyroid cancer	0.000196	0.00384	CcSEcCtD
Crizotinib—STK3—head—thyroid cancer	0.000196	0.00414	CbGeAlD
Crizotinib—TIE1—head—thyroid cancer	0.000196	0.00414	CbGeAlD
Crizotinib—SLK—trachea—thyroid cancer	0.000195	0.00412	CbGeAlD
Crizotinib—EPHB4—trachea—thyroid cancer	0.000194	0.00409	CbGeAlD
Crizotinib—Nervous system disorder—Vandetanib—thyroid cancer	0.000194	0.00379	CcSEcCtD
Crizotinib—JAK2—trachea—thyroid cancer	0.000193	0.00406	CbGeAlD
Crizotinib—ABL2—thyroid gland—thyroid cancer	0.000192	0.00405	CbGeAlD
Crizotinib—MAPK7—lymph node—thyroid cancer	0.000192	0.00405	CbGeAlD
Crizotinib—TXK—lymph node—thyroid cancer	0.000192	0.00405	CbGeAlD
Crizotinib—Skin disorder—Vandetanib—thyroid cancer	0.000192	0.00376	CcSEcCtD
Crizotinib—AURKA—head—thyroid cancer	0.000191	0.00403	CbGeAlD
Crizotinib—EPHA2—trachea—thyroid cancer	0.00019	0.00401	CbGeAlD
Crizotinib—FES—lymph node—thyroid cancer	0.00019	0.00401	CbGeAlD
Crizotinib—BMP2K—thyroid gland—thyroid cancer	0.00019	0.004	CbGeAlD
Crizotinib—TESK1—head—thyroid cancer	0.00019	0.004	CbGeAlD
Crizotinib—MAP4K5—trachea—thyroid cancer	0.000186	0.00392	CbGeAlD
Crizotinib—MAP3K3—trachea—thyroid cancer	0.000186	0.00392	CbGeAlD
Crizotinib—Urinary tract disorder—Sorafenib—thyroid cancer	0.000185	0.00363	CcSEcCtD
Crizotinib—MERTK—head—thyroid cancer	0.000184	0.00389	CbGeAlD
Crizotinib—Urethral disorder—Sorafenib—thyroid cancer	0.000184	0.0036	CcSEcCtD
Crizotinib—Burning sensation—Doxorubicin—thyroid cancer	0.000184	0.0036	CcSEcCtD
Crizotinib—Neuralgia—Doxorubicin—thyroid cancer	0.000184	0.0036	CcSEcCtD
Crizotinib—PTK2B—thyroid gland—thyroid cancer	0.000183	0.00386	CbGeAlD
Crizotinib—RIPK2—thyroid gland—thyroid cancer	0.000182	0.00383	CbGeAlD
Crizotinib—LIMK2—head—thyroid cancer	0.00018	0.0038	CbGeAlD
Crizotinib—MET—lymph node—thyroid cancer	0.00018	0.00379	CbGeAlD
Crizotinib—MAP3K12—head—thyroid cancer	0.000178	0.00376	CbGeAlD
Crizotinib—ACVR1—head—thyroid cancer	0.000178	0.00376	CbGeAlD
Crizotinib—EPHB6—trachea—thyroid cancer	0.000177	0.00374	CbGeAlD
Crizotinib—Paraesthesia—Vandetanib—thyroid cancer	0.000177	0.00347	CcSEcCtD
Crizotinib—Dyspnoea—Vandetanib—thyroid cancer	0.000176	0.00345	CcSEcCtD
Crizotinib—EPHA4—thyroid gland—thyroid cancer	0.000176	0.0037	CbGeAlD
Crizotinib—STK35—head—thyroid cancer	0.000175	0.00369	CbGeAlD
Crizotinib—Abscess—Epirubicin—thyroid cancer	0.000174	0.00342	CcSEcCtD
Crizotinib—Cardiac disorder—Sorafenib—thyroid cancer	0.000174	0.00341	CcSEcCtD
Crizotinib—Dyspepsia—Vandetanib—thyroid cancer	0.000174	0.00341	CcSEcCtD
Crizotinib—CDK7—lymph node—thyroid cancer	0.000174	0.00366	CbGeAlD
Crizotinib—TAOK2—lymph node—thyroid cancer	0.000172	0.00363	CbGeAlD
Crizotinib—MAP3K2—thyroid gland—thyroid cancer	0.000172	0.00363	CbGeAlD
Crizotinib—Decreased appetite—Vandetanib—thyroid cancer	0.000172	0.00336	CcSEcCtD
Crizotinib—YES1—trachea—thyroid cancer	0.000171	0.00362	CbGeAlD
Crizotinib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00017	0.00334	CcSEcCtD
Crizotinib—Fatigue—Vandetanib—thyroid cancer	0.00017	0.00334	CcSEcCtD
Crizotinib—TAOK3—trachea—thyroid cancer	0.000169	0.00357	CbGeAlD
Crizotinib—Mediastinal disorder—Sorafenib—thyroid cancer	0.000169	0.00331	CcSEcCtD
Crizotinib—Constipation—Vandetanib—thyroid cancer	0.000169	0.00331	CcSEcCtD
Crizotinib—PTK2—thyroid gland—thyroid cancer	0.000169	0.00356	CbGeAlD
Crizotinib—TBK1—thyroid gland—thyroid cancer	0.000169	0.00356	CbGeAlD
Crizotinib—BMP2K—head—thyroid cancer	0.000168	0.00355	CbGeAlD
Crizotinib—TYK2—thyroid gland—thyroid cancer	0.000167	0.00353	CbGeAlD
Crizotinib—Arrhythmia—Sorafenib—thyroid cancer	0.000167	0.00328	CcSEcCtD
Crizotinib—EPHA3—lymph node—thyroid cancer	0.000166	0.0035	CbGeAlD
Crizotinib—ACVR1B—lymph node—thyroid cancer	0.000166	0.0035	CbGeAlD
Crizotinib—IRAK1—thyroid gland—thyroid cancer	0.000165	0.00349	CbGeAlD
Crizotinib—Malnutrition—Sorafenib—thyroid cancer	0.000163	0.0032	CcSEcCtD
Crizotinib—PTK2B—head—thyroid cancer	0.000162	0.00343	CbGeAlD
Crizotinib—RPS6KB1—thyroid gland—thyroid cancer	0.000162	0.00342	CbGeAlD
Crizotinib—Abscess—Doxorubicin—thyroid cancer	0.000161	0.00316	CcSEcCtD
Crizotinib—LCK—thyroid gland—thyroid cancer	0.000161	0.0034	CbGeAlD
Crizotinib—FGR—thyroid gland—thyroid cancer	0.000161	0.0034	CbGeAlD
Crizotinib—RIPK2—head—thyroid cancer	0.000161	0.0034	CbGeAlD
Crizotinib—AXL—thyroid gland—thyroid cancer	0.000161	0.00339	CbGeAlD
Crizotinib—Dysgeusia—Sorafenib—thyroid cancer	0.00016	0.00313	CcSEcCtD
Crizotinib—JAK3—lymph node—thyroid cancer	0.000158	0.00334	CbGeAlD
Crizotinib—DCLK1—lymph node—thyroid cancer	0.000157	0.00332	CbGeAlD
Crizotinib—PLK4—lymph node—thyroid cancer	0.000156	0.0033	CbGeAlD
Crizotinib—Body temperature increased—Vandetanib—thyroid cancer	0.000156	0.00306	CcSEcCtD
Crizotinib—EPHA4—head—thyroid cancer	0.000156	0.00329	CbGeAlD
Crizotinib—STK4—lymph node—thyroid cancer	0.000155	0.00328	CbGeAlD
Crizotinib—SLK—thyroid gland—thyroid cancer	0.000155	0.00326	CbGeAlD
Crizotinib—EPHB4—thyroid gland—thyroid cancer	0.000153	0.00324	CbGeAlD
Crizotinib—MAP3K2—head—thyroid cancer	0.000153	0.00322	CbGeAlD
Crizotinib—JAK2—thyroid gland—thyroid cancer	0.000152	0.00321	CbGeAlD
Crizotinib—ABL1—saliva-secreting gland—thyroid cancer	0.000152	0.0032	CbGeAlD
Crizotinib—Anaemia—Sorafenib—thyroid cancer	0.000151	0.00296	CcSEcCtD
Crizotinib—EPHA2—thyroid gland—thyroid cancer	0.000151	0.00318	CbGeAlD
Crizotinib—TBK1—head—thyroid cancer	0.00015	0.00316	CbGeAlD
Crizotinib—PTK2—head—thyroid cancer	0.00015	0.00316	CbGeAlD
Crizotinib—TYK2—head—thyroid cancer	0.000149	0.00313	CbGeAlD
Crizotinib—CSF1R—trachea—thyroid cancer	0.000148	0.00312	CbGeAlD
Crizotinib—ALK—lymph node—thyroid cancer	0.000147	0.0031	CbGeAlD
Crizotinib—FER—lymph node—thyroid cancer	0.000147	0.0031	CbGeAlD
Crizotinib—TEK—thyroid gland—thyroid cancer	0.000147	0.0031	CbGeAlD
Crizotinib—MAP3K3—thyroid gland—thyroid cancer	0.000147	0.0031	CbGeAlD
Crizotinib—MAP4K5—thyroid gland—thyroid cancer	0.000147	0.0031	CbGeAlD
Crizotinib—Syncope—Sorafenib—thyroid cancer	0.000146	0.00287	CcSEcCtD
Crizotinib—Leukopenia—Sorafenib—thyroid cancer	0.000146	0.00286	CcSEcCtD
Crizotinib—TNK1—lymph node—thyroid cancer	0.000145	0.00307	CbGeAlD
Crizotinib—BMPR1B—lymph node—thyroid cancer	0.000144	0.00304	CbGeAlD
Crizotinib—MAP4K1—lymph node—thyroid cancer	0.000144	0.00304	CbGeAlD
Crizotinib—RPS6KB1—head—thyroid cancer	0.000144	0.00304	CbGeAlD
Crizotinib—Loss of consciousness—Sorafenib—thyroid cancer	0.000143	0.00281	CcSEcCtD
Crizotinib—FGR—head—thyroid cancer	0.000143	0.00302	CbGeAlD
Crizotinib—AXL—head—thyroid cancer	0.000142	0.003	CbGeAlD
Crizotinib—Asthenia—Vandetanib—thyroid cancer	0.000142	0.00278	CcSEcCtD
Crizotinib—Gait disturbance—Epirubicin—thyroid cancer	0.000141	0.00277	CcSEcCtD
Crizotinib—IGF1R—lymph node—thyroid cancer	0.000141	0.00298	CbGeAlD
Crizotinib—TNK2—lymph node—thyroid cancer	0.000141	0.00298	CbGeAlD
Crizotinib—EPHB6—thyroid gland—thyroid cancer	0.00014	0.00296	CbGeAlD
Crizotinib—MAP4K2—lymph node—thyroid cancer	0.000139	0.00294	CbGeAlD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000138	0.0027	CcSEcCtD
Crizotinib—Pulmonary embolism—Epirubicin—thyroid cancer	0.000138	0.0027	CcSEcCtD
Crizotinib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000138	0.0027	CcSEcCtD
Crizotinib—STK3—lymph node—thyroid cancer	0.000137	0.0029	CbGeAlD
Crizotinib—TIE1—lymph node—thyroid cancer	0.000137	0.0029	CbGeAlD
Crizotinib—YES1—thyroid gland—thyroid cancer	0.000136	0.00286	CbGeAlD
Crizotinib—JAK2—head—thyroid cancer	0.000135	0.00285	CbGeAlD
Crizotinib—Diarrhoea—Vandetanib—thyroid cancer	0.000135	0.00265	CcSEcCtD
Crizotinib—CYP3A4—Doxorubicin—thyroid cancer	0.000135	0.00028	CbGbCtD
Crizotinib—STK10—thyroid gland—thyroid cancer	0.000134	0.00284	CbGeAlD
Crizotinib—TAOK3—thyroid gland—thyroid cancer	0.000134	0.00282	CbGeAlD
Crizotinib—AURKA—lymph node—thyroid cancer	0.000134	0.00282	CbGeAlD
Crizotinib—EPHA2—head—thyroid cancer	0.000134	0.00282	CbGeAlD
Crizotinib—TESK1—lymph node—thyroid cancer	0.000133	0.0028	CbGeAlD
Crizotinib—Infection—Sorafenib—thyroid cancer	0.000132	0.00259	CcSEcCtD
Crizotinib—Shock—Sorafenib—thyroid cancer	0.000131	0.00257	CcSEcCtD
Crizotinib—Fluid retention—Epirubicin—thyroid cancer	0.000131	0.00257	CcSEcCtD
Crizotinib—Gait disturbance—Doxorubicin—thyroid cancer	0.000131	0.00256	CcSEcCtD
Crizotinib—Nervous system disorder—Sorafenib—thyroid cancer	0.000131	0.00256	CcSEcCtD
Crizotinib—Dizziness—Vandetanib—thyroid cancer	0.000131	0.00256	CcSEcCtD
Crizotinib—SRC—thyroid gland—thyroid cancer	0.00013	0.00275	CbGeAlD
Crizotinib—MAP4K5—head—thyroid cancer	0.00013	0.00275	CbGeAlD
Crizotinib—MAP3K3—head—thyroid cancer	0.00013	0.00275	CbGeAlD
Crizotinib—TEK—head—thyroid cancer	0.00013	0.00275	CbGeAlD
Crizotinib—Neuropathy—Epirubicin—thyroid cancer	0.000129	0.00254	CcSEcCtD
Crizotinib—Skin disorder—Sorafenib—thyroid cancer	0.000129	0.00253	CcSEcCtD
Crizotinib—MERTK—lymph node—thyroid cancer	0.000129	0.00272	CbGeAlD
Crizotinib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.000128	0.0025	CcSEcCtD
Crizotinib—Pulmonary embolism—Doxorubicin—thyroid cancer	0.000128	0.0025	CcSEcCtD
Crizotinib—IGF1R—Idarubicin—Epirubicin—thyroid cancer	0.000127	0.0739	CbGdCrCtD
Crizotinib—LIMK2—lymph node—thyroid cancer	0.000126	0.00266	CbGeAlD
Crizotinib—NUAK2—lymph node—thyroid cancer	0.000126	0.00265	CbGeAlD
Crizotinib—Vomiting—Vandetanib—thyroid cancer	0.000125	0.00246	CcSEcCtD
Crizotinib—ACVR1—lymph node—thyroid cancer	0.000125	0.00263	CbGeAlD
Crizotinib—MAP3K12—lymph node—thyroid cancer	0.000125	0.00263	CbGeAlD
Crizotinib—FLT3—lymph node—thyroid cancer	0.000125	0.00263	CbGeAlD
Crizotinib—EPHB6—head—thyroid cancer	0.000125	0.00263	CbGeAlD
Crizotinib—Rash—Vandetanib—thyroid cancer	0.000124	0.00244	CcSEcCtD
Crizotinib—Dermatitis—Vandetanib—thyroid cancer	0.000124	0.00244	CcSEcCtD
Crizotinib—STK35—lymph node—thyroid cancer	0.000122	0.00258	CbGeAlD
Crizotinib—Fluid retention—Doxorubicin—thyroid cancer	0.000121	0.00237	CcSEcCtD
Crizotinib—YES1—head—thyroid cancer	0.00012	0.00254	CbGeAlD
Crizotinib—Neuropathy—Doxorubicin—thyroid cancer	0.00012	0.00235	CcSEcCtD
Crizotinib—Sepsis—Epirubicin—thyroid cancer	0.00012	0.00235	CcSEcCtD
Crizotinib—ABL2—lymph node—thyroid cancer	0.000119	0.00252	CbGeAlD
Crizotinib—STK10—head—thyroid cancer	0.000119	0.00252	CbGeAlD
Crizotinib—TAOK3—head—thyroid cancer	0.000119	0.00251	CbGeAlD
Crizotinib—Dyspnoea—Sorafenib—thyroid cancer	0.000119	0.00233	CcSEcCtD
Crizotinib—BMP2K—lymph node—thyroid cancer	0.000118	0.00248	CbGeAlD
Crizotinib—IGF1R—Idarubicin—Doxorubicin—thyroid cancer	0.000118	0.0684	CbGdCrCtD
Crizotinib—Nausea—Vandetanib—thyroid cancer	0.000117	0.0023	CcSEcCtD
Crizotinib—Dyspepsia—Sorafenib—thyroid cancer	0.000117	0.0023	CcSEcCtD
Crizotinib—CSF1R—thyroid gland—thyroid cancer	0.000117	0.00247	CbGeAlD
Crizotinib—ABL1—trachea—thyroid cancer	0.000117	0.00247	CbGeAlD
Crizotinib—SRC—head—thyroid cancer	0.000116	0.00244	CbGeAlD
Crizotinib—Decreased appetite—Sorafenib—thyroid cancer	0.000116	0.00227	CcSEcCtD
Crizotinib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000115	0.00226	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000115	0.00225	CcSEcCtD
Crizotinib—Fatigue—Sorafenib—thyroid cancer	0.000115	0.00225	CcSEcCtD
Crizotinib—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000115	0.00225	CcSEcCtD
Crizotinib—Constipation—Sorafenib—thyroid cancer	0.000114	0.00223	CcSEcCtD
Crizotinib—PTK2B—lymph node—thyroid cancer	0.000114	0.0024	CbGeAlD
Crizotinib—RIPK2—lymph node—thyroid cancer	0.000113	0.00238	CbGeAlD
Crizotinib—Hepatic failure—Epirubicin—thyroid cancer	0.000111	0.00218	CcSEcCtD
Crizotinib—Sepsis—Doxorubicin—thyroid cancer	0.000111	0.00217	CcSEcCtD
Crizotinib—EPHA4—lymph node—thyroid cancer	0.000109	0.0023	CbGeAlD
Crizotinib—MAP3K2—lymph node—thyroid cancer	0.000107	0.00226	CbGeAlD
Crizotinib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000106	0.00209	CcSEcCtD
Crizotinib—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000106	0.00208	CcSEcCtD
Crizotinib—Body temperature increased—Sorafenib—thyroid cancer	0.000105	0.00206	CcSEcCtD
Crizotinib—PTK2—lymph node—thyroid cancer	0.000105	0.00221	CbGeAlD
Crizotinib—TBK1—lymph node—thyroid cancer	0.000105	0.00221	CbGeAlD
Crizotinib—TYK2—lymph node—thyroid cancer	0.000104	0.00219	CbGeAlD
Crizotinib—CSF1R—head—thyroid cancer	0.000104	0.00219	CbGeAlD
Crizotinib—Hepatic failure—Doxorubicin—thyroid cancer	0.000103	0.00202	CcSEcCtD
Crizotinib—IRAK1—lymph node—thyroid cancer	0.000103	0.00217	CbGeAlD
Crizotinib—CDK7—Idarubicin—Epirubicin—thyroid cancer	0.000102	0.0596	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Epirubicin—thyroid cancer	0.000102	0.0596	CbGdCrCtD
Crizotinib—CDK7—Doxorubicin—Epirubicin—thyroid cancer	0.000102	0.0596	CbGdCrCtD
Crizotinib—RPS6KB1—lymph node—thyroid cancer	0.000101	0.00213	CbGeAlD
Crizotinib—LCK—lymph node—thyroid cancer	0.0001	0.00211	CbGeAlD
Crizotinib—FGR—lymph node—thyroid cancer	0.0001	0.00211	CbGeAlD
Crizotinib—Diplopia—Epirubicin—thyroid cancer	0.0001	0.00196	CcSEcCtD
Crizotinib—AXL—lymph node—thyroid cancer	9.98e-05	0.0021	CbGeAlD
Crizotinib—Face oedema—Epirubicin—thyroid cancer	9.66e-05	0.00189	CcSEcCtD
Crizotinib—SLK—lymph node—thyroid cancer	9.6e-05	0.00203	CbGeAlD
Crizotinib—Asthenia—Sorafenib—thyroid cancer	9.55e-05	0.00187	CcSEcCtD
Crizotinib—EPHB4—lymph node—thyroid cancer	9.53e-05	0.00201	CbGeAlD
Crizotinib—CDK7—Idarubicin—Doxorubicin—thyroid cancer	9.48e-05	0.0551	CbGdCrCtD
Crizotinib—CDK7—Epirubicin—Doxorubicin—thyroid cancer	9.48e-05	0.0551	CbGdCrCtD
Crizotinib—CDK7—Daunorubicin—Doxorubicin—thyroid cancer	9.48e-05	0.0551	CbGdCrCtD
Crizotinib—JAK2—lymph node—thyroid cancer	9.47e-05	0.002	CbGeAlD
Crizotinib—EPHA2—lymph node—thyroid cancer	9.35e-05	0.00197	CbGeAlD
Crizotinib—Diplopia—Doxorubicin—thyroid cancer	9.26e-05	0.00182	CcSEcCtD
Crizotinib—ABL1—thyroid gland—thyroid cancer	9.26e-05	0.00195	CbGeAlD
Crizotinib—MAP4K5—lymph node—thyroid cancer	9.12e-05	0.00192	CbGeAlD
Crizotinib—MAP3K3—lymph node—thyroid cancer	9.12e-05	0.00192	CbGeAlD
Crizotinib—TEK—lymph node—thyroid cancer	9.12e-05	0.00192	CbGeAlD
Crizotinib—Hypokalaemia—Epirubicin—thyroid cancer	9.11e-05	0.00179	CcSEcCtD
Crizotinib—Diarrhoea—Sorafenib—thyroid cancer	9.11e-05	0.00179	CcSEcCtD
Crizotinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	9.02e-05	0.00177	CcSEcCtD
Crizotinib—Face oedema—Doxorubicin—thyroid cancer	8.94e-05	0.00175	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	8.83e-05	0.00173	CcSEcCtD
Crizotinib—Muscular weakness—Epirubicin—thyroid cancer	8.83e-05	0.00173	CcSEcCtD
Crizotinib—Dizziness—Sorafenib—thyroid cancer	8.8e-05	0.00173	CcSEcCtD
Crizotinib—EPHB6—lymph node—thyroid cancer	8.72e-05	0.00184	CbGeAlD
Crizotinib—Vomiting—Sorafenib—thyroid cancer	8.47e-05	0.00166	CcSEcCtD
Crizotinib—Hypokalaemia—Doxorubicin—thyroid cancer	8.43e-05	0.00165	CcSEcCtD
Crizotinib—YES1—lymph node—thyroid cancer	8.43e-05	0.00178	CbGeAlD
Crizotinib—Rash—Sorafenib—thyroid cancer	8.39e-05	0.00165	CcSEcCtD
Crizotinib—Dermatitis—Sorafenib—thyroid cancer	8.39e-05	0.00164	CcSEcCtD
Crizotinib—STK10—lymph node—thyroid cancer	8.35e-05	0.00176	CbGeAlD
Crizotinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	8.34e-05	0.00163	CcSEcCtD
Crizotinib—TAOK3—lymph node—thyroid cancer	8.32e-05	0.00175	CbGeAlD
Crizotinib—ABL1—head—thyroid cancer	8.22e-05	0.00173	CbGeAlD
Crizotinib—Muscular weakness—Doxorubicin—thyroid cancer	8.17e-05	0.0016	CcSEcCtD
Crizotinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	8.17e-05	0.0016	CcSEcCtD
Crizotinib—SRC—lymph node—thyroid cancer	8.11e-05	0.00171	CbGeAlD
Crizotinib—Neutropenia—Epirubicin—thyroid cancer	8.09e-05	0.00159	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	8.04e-05	0.00158	CcSEcCtD
Crizotinib—Nausea—Sorafenib—thyroid cancer	7.91e-05	0.00155	CcSEcCtD
Crizotinib—Weight decreased—Epirubicin—thyroid cancer	7.83e-05	0.00153	CcSEcCtD
Crizotinib—Pneumonia—Epirubicin—thyroid cancer	7.76e-05	0.00152	CcSEcCtD
Crizotinib—Infestation NOS—Epirubicin—thyroid cancer	7.71e-05	0.00151	CcSEcCtD
Crizotinib—Infestation—Epirubicin—thyroid cancer	7.71e-05	0.00151	CcSEcCtD
Crizotinib—Neuropathy peripheral—Epirubicin—thyroid cancer	7.56e-05	0.00148	CcSEcCtD
Crizotinib—Neutropenia—Doxorubicin—thyroid cancer	7.49e-05	0.00147	CcSEcCtD
Crizotinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	7.44e-05	0.00146	CcSEcCtD
Crizotinib—Hepatobiliary disease—Epirubicin—thyroid cancer	7.3e-05	0.00143	CcSEcCtD
Crizotinib—CSF1R—lymph node—thyroid cancer	7.28e-05	0.00153	CbGeAlD
Crizotinib—Weight decreased—Doxorubicin—thyroid cancer	7.24e-05	0.00142	CcSEcCtD
Crizotinib—Pneumonia—Doxorubicin—thyroid cancer	7.18e-05	0.00141	CcSEcCtD
Crizotinib—Infestation—Doxorubicin—thyroid cancer	7.14e-05	0.0014	CcSEcCtD
Crizotinib—Infestation NOS—Doxorubicin—thyroid cancer	7.14e-05	0.0014	CcSEcCtD
Crizotinib—Bradycardia—Epirubicin—thyroid cancer	7.05e-05	0.00138	CcSEcCtD
Crizotinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	7e-05	0.00137	CcSEcCtD
Crizotinib—Hypoaesthesia—Epirubicin—thyroid cancer	6.89e-05	0.00135	CcSEcCtD
Crizotinib—Urinary tract disorder—Epirubicin—thyroid cancer	6.84e-05	0.00134	CcSEcCtD
Crizotinib—Oedema peripheral—Epirubicin—thyroid cancer	6.82e-05	0.00134	CcSEcCtD
Crizotinib—Urethral disorder—Epirubicin—thyroid cancer	6.79e-05	0.00133	CcSEcCtD
Crizotinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	6.75e-05	0.00132	CcSEcCtD
Crizotinib—PLK4—Doxorubicin—Epirubicin—thyroid cancer	6.67e-05	0.0388	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Epirubicin—thyroid cancer	6.67e-05	0.0388	CbGdCrCtD
Crizotinib—Visual impairment—Epirubicin—thyroid cancer	6.67e-05	0.00131	CcSEcCtD
Crizotinib—Bradycardia—Doxorubicin—thyroid cancer	6.52e-05	0.00128	CcSEcCtD
Crizotinib—Eye disorder—Epirubicin—thyroid cancer	6.47e-05	0.00127	CcSEcCtD
Crizotinib—Cardiac disorder—Epirubicin—thyroid cancer	6.43e-05	0.00126	CcSEcCtD
Crizotinib—Hypoaesthesia—Doxorubicin—thyroid cancer	6.38e-05	0.00125	CcSEcCtD
Crizotinib—Urinary tract disorder—Doxorubicin—thyroid cancer	6.33e-05	0.00124	CcSEcCtD
Crizotinib—Oedema peripheral—Doxorubicin—thyroid cancer	6.31e-05	0.00124	CcSEcCtD
Crizotinib—Urethral disorder—Doxorubicin—thyroid cancer	6.28e-05	0.00123	CcSEcCtD
Crizotinib—Mediastinal disorder—Epirubicin—thyroid cancer	6.24e-05	0.00122	CcSEcCtD
Crizotinib—Arrhythmia—Epirubicin—thyroid cancer	6.19e-05	0.00121	CcSEcCtD
Crizotinib—PLK4—Epirubicin—Doxorubicin—thyroid cancer	6.18e-05	0.0359	CbGdCrCtD
Crizotinib—PLK4—Idarubicin—Doxorubicin—thyroid cancer	6.18e-05	0.0359	CbGdCrCtD
Crizotinib—Visual impairment—Doxorubicin—thyroid cancer	6.18e-05	0.00121	CcSEcCtD
Crizotinib—Malnutrition—Epirubicin—thyroid cancer	6.03e-05	0.00118	CcSEcCtD
Crizotinib—Eye disorder—Doxorubicin—thyroid cancer	5.99e-05	0.00117	CcSEcCtD
Crizotinib—Cardiac disorder—Doxorubicin—thyroid cancer	5.95e-05	0.00117	CcSEcCtD
Crizotinib—Dysgeusia—Epirubicin—thyroid cancer	5.9e-05	0.00116	CcSEcCtD
Crizotinib—Mediastinal disorder—Doxorubicin—thyroid cancer	5.78e-05	0.00113	CcSEcCtD
Crizotinib—ABL1—lymph node—thyroid cancer	5.75e-05	0.00121	CbGeAlD
Crizotinib—Arrhythmia—Doxorubicin—thyroid cancer	5.72e-05	0.00112	CcSEcCtD
Crizotinib—Vision blurred—Epirubicin—thyroid cancer	5.68e-05	0.00111	CcSEcCtD
Crizotinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	5.61e-05	0.0326	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	5.61e-05	0.0326	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	5.61e-05	0.0326	CbGdCrCtD
Crizotinib—Malnutrition—Doxorubicin—thyroid cancer	5.58e-05	0.00109	CcSEcCtD
Crizotinib—Anaemia—Epirubicin—thyroid cancer	5.57e-05	0.00109	CcSEcCtD
Crizotinib—Dysgeusia—Doxorubicin—thyroid cancer	5.46e-05	0.00107	CcSEcCtD
Crizotinib—Syncope—Epirubicin—thyroid cancer	5.41e-05	0.00106	CcSEcCtD
Crizotinib—Leukopenia—Epirubicin—thyroid cancer	5.4e-05	0.00106	CcSEcCtD
Crizotinib—Loss of consciousness—Epirubicin—thyroid cancer	5.3e-05	0.00104	CcSEcCtD
Crizotinib—Vision blurred—Doxorubicin—thyroid cancer	5.26e-05	0.00103	CcSEcCtD
Crizotinib—AURKA—Doxorubicin—Epirubicin—thyroid cancer	5.23e-05	0.0304	CbGdCrCtD
Crizotinib—AURKA—Idarubicin—Epirubicin—thyroid cancer	5.23e-05	0.0304	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Epirubicin—thyroid cancer	5.23e-05	0.0304	CbGdCrCtD
Crizotinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	5.19e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	5.19e-05	0.0302	CbGdCrCtD
Crizotinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	5.19e-05	0.0302	CbGdCrCtD
Crizotinib—Anaemia—Doxorubicin—thyroid cancer	5.16e-05	0.00101	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	5.1e-05	0.000999	CcSEcCtD
Crizotinib—Syncope—Doxorubicin—thyroid cancer	5e-05	0.00098	CcSEcCtD
Crizotinib—Leukopenia—Doxorubicin—thyroid cancer	4.99e-05	0.000979	CcSEcCtD
Crizotinib—Oedema—Epirubicin—thyroid cancer	4.92e-05	0.000964	CcSEcCtD
Crizotinib—Loss of consciousness—Doxorubicin—thyroid cancer	4.9e-05	0.000961	CcSEcCtD
Crizotinib—Infection—Epirubicin—thyroid cancer	4.89e-05	0.000958	CcSEcCtD
Crizotinib—Shock—Epirubicin—thyroid cancer	4.84e-05	0.000949	CcSEcCtD
Crizotinib—AURKA—Idarubicin—Doxorubicin—thyroid cancer	4.84e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Daunorubicin—Doxorubicin—thyroid cancer	4.84e-05	0.0281	CbGdCrCtD
Crizotinib—AURKA—Epirubicin—Doxorubicin—thyroid cancer	4.84e-05	0.0281	CbGdCrCtD
Crizotinib—Nervous system disorder—Epirubicin—thyroid cancer	4.83e-05	0.000946	CcSEcCtD
Crizotinib—Skin disorder—Epirubicin—thyroid cancer	4.78e-05	0.000937	CcSEcCtD
Crizotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	4.72e-05	0.000924	CcSEcCtD
Crizotinib—Oedema—Doxorubicin—thyroid cancer	4.55e-05	0.000892	CcSEcCtD
Crizotinib—Infection—Doxorubicin—thyroid cancer	4.52e-05	0.000886	CcSEcCtD
Crizotinib—Shock—Doxorubicin—thyroid cancer	4.48e-05	0.000878	CcSEcCtD
Crizotinib—Nervous system disorder—Doxorubicin—thyroid cancer	4.46e-05	0.000875	CcSEcCtD
Crizotinib—Skin disorder—Doxorubicin—thyroid cancer	4.42e-05	0.000867	CcSEcCtD
Crizotinib—Paraesthesia—Epirubicin—thyroid cancer	4.42e-05	0.000866	CcSEcCtD
Crizotinib—Dyspnoea—Epirubicin—thyroid cancer	4.39e-05	0.00086	CcSEcCtD
Crizotinib—Dyspepsia—Epirubicin—thyroid cancer	4.33e-05	0.000849	CcSEcCtD
Crizotinib—Decreased appetite—Epirubicin—thyroid cancer	4.28e-05	0.000838	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	4.25e-05	0.000833	CcSEcCtD
Crizotinib—Fatigue—Epirubicin—thyroid cancer	4.24e-05	0.000831	CcSEcCtD
Crizotinib—Constipation—Epirubicin—thyroid cancer	4.21e-05	0.000825	CcSEcCtD
Crizotinib—Paraesthesia—Doxorubicin—thyroid cancer	4.09e-05	0.000801	CcSEcCtD
Crizotinib—Dyspnoea—Doxorubicin—thyroid cancer	4.06e-05	0.000796	CcSEcCtD
Crizotinib—Dyspepsia—Doxorubicin—thyroid cancer	4.01e-05	0.000785	CcSEcCtD
Crizotinib—Decreased appetite—Doxorubicin—thyroid cancer	3.96e-05	0.000776	CcSEcCtD
Crizotinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	3.93e-05	0.00077	CcSEcCtD
Crizotinib—Fatigue—Doxorubicin—thyroid cancer	3.93e-05	0.000769	CcSEcCtD
Crizotinib—Constipation—Doxorubicin—thyroid cancer	3.89e-05	0.000763	CcSEcCtD
Crizotinib—Body temperature increased—Epirubicin—thyroid cancer	3.89e-05	0.000762	CcSEcCtD
Crizotinib—ABCB1—trachea—thyroid cancer	3.64e-05	0.000768	CbGeAlD
Crizotinib—Body temperature increased—Doxorubicin—thyroid cancer	3.6e-05	0.000705	CcSEcCtD
Crizotinib—Asthenia—Epirubicin—thyroid cancer	3.53e-05	0.000692	CcSEcCtD
Crizotinib—Diarrhoea—Epirubicin—thyroid cancer	3.37e-05	0.00066	CcSEcCtD
Crizotinib—Asthenia—Doxorubicin—thyroid cancer	3.27e-05	0.00064	CcSEcCtD
Crizotinib—Dizziness—Epirubicin—thyroid cancer	3.25e-05	0.000638	CcSEcCtD
Crizotinib—Vomiting—Epirubicin—thyroid cancer	3.13e-05	0.000613	CcSEcCtD
Crizotinib—Diarrhoea—Doxorubicin—thyroid cancer	3.12e-05	0.000611	CcSEcCtD
Crizotinib—Rash—Epirubicin—thyroid cancer	3.1e-05	0.000608	CcSEcCtD
Crizotinib—Dermatitis—Epirubicin—thyroid cancer	3.1e-05	0.000607	CcSEcCtD
Crizotinib—Dizziness—Doxorubicin—thyroid cancer	3.01e-05	0.00059	CcSEcCtD
Crizotinib—Nausea—Epirubicin—thyroid cancer	2.92e-05	0.000573	CcSEcCtD
Crizotinib—Vomiting—Doxorubicin—thyroid cancer	2.89e-05	0.000567	CcSEcCtD
Crizotinib—ABCB1—thyroid gland—thyroid cancer	2.88e-05	0.000607	CbGeAlD
Crizotinib—Rash—Doxorubicin—thyroid cancer	2.87e-05	0.000563	CcSEcCtD
Crizotinib—Dermatitis—Doxorubicin—thyroid cancer	2.87e-05	0.000562	CcSEcCtD
Crizotinib—Nausea—Doxorubicin—thyroid cancer	2.7e-05	0.00053	CcSEcCtD
Crizotinib—ABCB1—head—thyroid cancer	2.55e-05	0.000539	CbGeAlD
Crizotinib—ABCB1—lymph node—thyroid cancer	1.79e-05	0.000377	CbGeAlD
Crizotinib—SRC—Disease—HIF1A—thyroid cancer	1.39e-06	1.92e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—CCND1—thyroid cancer	1.39e-06	1.91e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—PTEN—thyroid cancer	1.38e-06	1.9e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HRAS—thyroid cancer	1.38e-06	1.89e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—NRAS—thyroid cancer	1.38e-06	1.89e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—BRAF—thyroid cancer	1.37e-06	1.89e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—HRAS—thyroid cancer	1.37e-06	1.89e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—NRAS—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—HRAS—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Crizotinib—JAK3—Immune System—AKT1—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—PTEN—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—AKT1—thyroid cancer	1.36e-06	1.87e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—HRAS—thyroid cancer	1.35e-06	1.86e-05	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—AKT1—thyroid cancer	1.35e-06	1.86e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—HRAS—thyroid cancer	1.35e-06	1.86e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—NRAS—thyroid cancer	1.35e-06	1.85e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HRAS—thyroid cancer	1.35e-06	1.85e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HIF1A—thyroid cancer	1.34e-06	1.85e-05	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—AKT1—thyroid cancer	1.34e-06	1.85e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—PTEN—thyroid cancer	1.34e-06	1.84e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—NRAS—thyroid cancer	1.34e-06	1.84e-05	CbGpPWpGaD
Crizotinib—LYN—Hemostasis—AKT1—thyroid cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—CCND1—thyroid cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—HRAS—thyroid cancer	1.33e-06	1.83e-05	CbGpPWpGaD
Crizotinib—ABL1—Hemostasis—AKT1—thyroid cancer	1.33e-06	1.82e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—HRAS—thyroid cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TERT—thyroid cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—HRAS—thyroid cancer	1.32e-06	1.81e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—KRAS—thyroid cancer	1.31e-06	1.81e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—KRAS—thyroid cancer	1.31e-06	1.8e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—HRAS—thyroid cancer	1.31e-06	1.79e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—BRAF—thyroid cancer	1.3e-06	1.79e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—NRAS—thyroid cancer	1.29e-06	1.78e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—TP53—thyroid cancer	1.29e-06	1.78e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—KRAS—thyroid cancer	1.29e-06	1.77e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—CCND1—thyroid cancer	1.29e-06	1.77e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRG1—thyroid cancer	1.28e-06	1.76e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—PTEN—thyroid cancer	1.28e-06	1.76e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—HRAS—thyroid cancer	1.27e-06	1.75e-05	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—AKT1—thyroid cancer	1.27e-06	1.75e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—KRAS—thyroid cancer	1.27e-06	1.74e-05	CbGpPWpGaD
Crizotinib—CDK7—Gene Expression—AKT1—thyroid cancer	1.26e-06	1.74e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—KRAS—thyroid cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—KRAS—thyroid cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HIF1A—thyroid cancer	1.26e-06	1.73e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—KRAS—thyroid cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Crizotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Crizotinib—JAK2—Hemostasis—AKT1—thyroid cancer	1.25e-06	1.72e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—PTEN—thyroid cancer	1.24e-06	1.71e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—HRAS—thyroid cancer	1.24e-06	1.7e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—NRAS—thyroid cancer	1.23e-06	1.7e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—RXRA—thyroid cancer	1.23e-06	1.69e-05	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—AKT1—thyroid cancer	1.22e-06	1.67e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—PTEN—thyroid cancer	1.21e-06	1.67e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—NRAS—thyroid cancer	1.21e-06	1.67e-05	CbGpPWpGaD
Crizotinib—RIPK2—Immune System—AKT1—thyroid cancer	1.21e-06	1.67e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—PTEN—thyroid cancer	1.21e-06	1.66e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTGS2—thyroid cancer	1.2e-06	1.65e-05	CbGpPWpGaD
Crizotinib—LYN—Innate Immune System—AKT1—thyroid cancer	1.2e-06	1.65e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—NRAS—thyroid cancer	1.2e-06	1.64e-05	CbGpPWpGaD
Crizotinib—ABL1—Innate Immune System—AKT1—thyroid cancer	1.19e-06	1.64e-05	CbGpPWpGaD
Crizotinib—PTK2B—Immune System—AKT1—thyroid cancer	1.19e-06	1.64e-05	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—AKT1—thyroid cancer	1.19e-06	1.64e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—KRAS—thyroid cancer	1.18e-06	1.63e-05	CbGpPWpGaD
Crizotinib—CDK7—Disease—AKT1—thyroid cancer	1.17e-06	1.61e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—KRAS—thyroid cancer	1.17e-06	1.61e-05	CbGpPWpGaD
Crizotinib—BLK—Immune System—AKT1—thyroid cancer	1.17e-06	1.6e-05	CbGpPWpGaD
Crizotinib—FGR—Immune System—AKT1—thyroid cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—KRAS—thyroid cancer	1.16e-06	1.6e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—BRAF—thyroid cancer	1.15e-06	1.59e-05	CbGpPWpGaD
Crizotinib—LYN—Adaptive Immune System—AKT1—thyroid cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TERT—thyroid cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—KRAS—thyroid cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—TP53—thyroid cancer	1.15e-06	1.58e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—NRAS—thyroid cancer	1.14e-06	1.57e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRG1—thyroid cancer	1.14e-06	1.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—PTEN—thyroid cancer	1.14e-06	1.56e-05	CbGpPWpGaD
Crizotinib—JAK2—Innate Immune System—AKT1—thyroid cancer	1.12e-06	1.54e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—HRAS—thyroid cancer	1.12e-06	1.54e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—KRAS—thyroid cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—HRAS—thyroid cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—BRAF—thyroid cancer	1.11e-06	1.53e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—NRAS—thyroid cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—NRAS—thyroid cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.11e-06	1.52e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—CCND1—thyroid cancer	1.1e-06	1.52e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	1.1e-06	1.52e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—HRAS—thyroid cancer	1.1e-06	1.51e-05	CbGpPWpGaD
Crizotinib—LCK—Hemostasis—AKT1—thyroid cancer	1.09e-06	1.5e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—CCND1—thyroid cancer	1.09e-06	1.5e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—NRAS—thyroid cancer	1.08e-06	1.49e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—NRAS—thyroid cancer	1.08e-06	1.48e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—HRAS—thyroid cancer	1.08e-06	1.48e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HRAS—thyroid cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—PTEN—thyroid cancer	1.07e-06	1.47e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—KRAS—thyroid cancer	1.06e-06	1.46e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—HRAS—thyroid cancer	1.06e-06	1.46e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTGS2—thyroid cancer	1.05e-06	1.45e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—PTEN—thyroid cancer	1.05e-06	1.45e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—PTEN—thyroid cancer	1.05e-06	1.44e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—KRAS—thyroid cancer	1.04e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—BRAF—thyroid cancer	1.04e-06	1.43e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—TP53—thyroid cancer	1.04e-06	1.43e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—CCND1—thyroid cancer	1.03e-06	1.42e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—KRAS—thyroid cancer	1.03e-06	1.41e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TERT—thyroid cancer	1.02e-06	1.4e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—NRAS—thyroid cancer	1.01e-06	1.39e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—HRAS—thyroid cancer	1.01e-06	1.38e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—CCND1—thyroid cancer	1e-06	1.38e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—PTEN—thyroid cancer	9.98e-07	1.37e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HRAS—thyroid cancer	9.95e-07	1.37e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—PTEN—thyroid cancer	9.94e-07	1.37e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—HRAS—thyroid cancer	9.86e-07	1.36e-05	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—AKT1—thyroid cancer	9.86e-07	1.36e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—KRAS—thyroid cancer	9.84e-07	1.35e-05	CbGpPWpGaD
Crizotinib—LCK—Innate Immune System—AKT1—thyroid cancer	9.84e-07	1.35e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—HRAS—thyroid cancer	9.78e-07	1.34e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HIF1A—thyroid cancer	9.76e-07	1.34e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—PTEN—thyroid cancer	9.68e-07	1.33e-05	CbGpPWpGaD
Crizotinib—SRC—Hemostasis—AKT1—thyroid cancer	9.67e-07	1.33e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—KRAS—thyroid cancer	9.55e-07	1.31e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—KRAS—thyroid cancer	9.54e-07	1.31e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—NRAS—thyroid cancer	9.52e-07	1.31e-05	CbGpPWpGaD
Crizotinib—PTK2—Immune System—AKT1—thyroid cancer	9.51e-07	1.31e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—HRAS—thyroid cancer	9.47e-07	1.3e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—AKT1—thyroid cancer	9.45e-07	1.3e-05	CbGpPWpGaD
Crizotinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	9.45e-07	1.3e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—NRAS—thyroid cancer	9.38e-07	1.29e-05	CbGpPWpGaD
Crizotinib—YES1—Immune System—AKT1—thyroid cancer	9.38e-07	1.29e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—NRAS—thyroid cancer	9.35e-07	1.29e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTGS2—thyroid cancer	9.32e-07	1.28e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—KRAS—thyroid cancer	9.31e-07	1.28e-05	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—RXRA—thyroid cancer	9.3e-07	1.28e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—TP53—thyroid cancer	9.28e-07	1.28e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—KRAS—thyroid cancer	9.27e-07	1.27e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—PTEN—thyroid cancer	9.18e-07	1.26e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—TP53—thyroid cancer	9.14e-07	1.26e-05	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—BRAF—thyroid cancer	9.13e-07	1.25e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—TPR—thyroid cancer	9.11e-07	1.25e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—HRAS—thyroid cancer	9.03e-07	1.24e-05	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	8.96e-07	1.23e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—NRAS—thyroid cancer	8.9e-07	1.22e-05	CbGpPWpGaD
Crizotinib—IRAK1—Immune System—AKT1—thyroid cancer	8.89e-07	1.22e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HRAS—thyroid cancer	8.87e-07	1.22e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—NRAS—thyroid cancer	8.87e-07	1.22e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—PTEN—thyroid cancer	8.8e-07	1.21e-05	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—AKT1—thyroid cancer	8.79e-07	1.21e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—TP53—thyroid cancer	8.75e-07	1.2e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HRAS—thyroid cancer	8.74e-07	1.2e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—KRAS—thyroid cancer	8.72e-07	1.2e-05	CbGpPWpGaD
Crizotinib—SRC—Innate Immune System—AKT1—thyroid cancer	8.71e-07	1.2e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—NRAS—thyroid cancer	8.64e-07	1.19e-05	CbGpPWpGaD
Crizotinib—TYK2—Immune System—AKT1—thyroid cancer	8.63e-07	1.19e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—TP53—thyroid cancer	8.48e-07	1.17e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HRAS—thyroid cancer	8.37e-07	1.15e-05	CbGpPWpGaD
Crizotinib—SRC—Adaptive Immune System—AKT1—thyroid cancer	8.36e-07	1.15e-05	CbGpPWpGaD
Crizotinib—LCK—Disease—NRAS—thyroid cancer	8.19e-07	1.13e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—KRAS—thyroid cancer	8.19e-07	1.13e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—PTEN—thyroid cancer	8.13e-07	1.12e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—CCND1—thyroid cancer	8.13e-07	1.12e-05	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HRAS—thyroid cancer	8.11e-07	1.12e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HRAS—thyroid cancer	8.11e-07	1.11e-05	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—BRAF—thyroid cancer	8.08e-07	1.11e-05	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—KRAS—thyroid cancer	8.08e-07	1.11e-05	CbGpPWpGaD
Crizotinib—JAK2—Disease—KRAS—thyroid cancer	8.05e-07	1.11e-05	CbGpPWpGaD
Crizotinib—TYK2—Disease—AKT1—thyroid cancer	7.97e-07	1.1e-05	CbGpPWpGaD
Crizotinib—LYN—Immune System—HRAS—thyroid cancer	7.92e-07	1.09e-05	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—AKT1—thyroid cancer	7.88e-07	1.08e-05	CbGpPWpGaD
Crizotinib—ABL1—Immune System—HRAS—thyroid cancer	7.88e-07	1.08e-05	CbGpPWpGaD
Crizotinib—SRC—Immune System—NRAS—thyroid cancer	7.85e-07	1.08e-05	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—PTEN—thyroid cancer	7.84e-07	1.08e-05	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—AKT1—thyroid cancer	7.83e-07	1.08e-05	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PPARG—thyroid cancer	7.78e-07	1.07e-05	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—AKT1—thyroid cancer	7.72e-07	1.06e-05	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—KRAS—thyroid cancer	7.66e-07	1.05e-05	CbGpPWpGaD
Crizotinib—LCK—Immune System—KRAS—thyroid cancer	7.63e-07	1.05e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—CCND1—thyroid cancer	7.6e-07	1.05e-05	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—KRAS—thyroid cancer	7.44e-07	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Immune System—HRAS—thyroid cancer	7.41e-07	1.02e-05	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—AKT1—thyroid cancer	7.39e-07	1.02e-05	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—PTEN—thyroid cancer	7.34e-07	1.01e-05	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—TP53—thyroid cancer	7.28e-07	1e-05	CbGpPWpGaD
Crizotinib—SRC—Disease—NRAS—thyroid cancer	7.25e-07	9.97e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—TP53—thyroid cancer	7.18e-07	9.87e-06	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—AKT1—thyroid cancer	7.16e-07	9.85e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—AKT1—thyroid cancer	7.16e-07	9.84e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—KRAS—thyroid cancer	7.05e-07	9.69e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—NRAS—thyroid cancer	7e-07	9.62e-06	CbGpPWpGaD
Crizotinib—LYN—Immune System—AKT1—thyroid cancer	6.99e-07	9.61e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HRAS—thyroid cancer	6.96e-07	9.57e-06	CbGpPWpGaD
Crizotinib—ABL1—Immune System—AKT1—thyroid cancer	6.96e-07	9.57e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HRAS—thyroid cancer	6.86e-07	9.44e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—HRAS—thyroid cancer	6.84e-07	9.41e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	6.82e-07	9.37e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—TP53—thyroid cancer	6.81e-07	9.36e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—KRAS—thyroid cancer	6.76e-07	9.29e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—CCND1—thyroid cancer	6.66e-07	9.16e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—TP53—thyroid cancer	6.61e-07	9.09e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—NRAS—thyroid cancer	6.55e-07	9e-06	CbGpPWpGaD
Crizotinib—JAK2—Immune System—AKT1—thyroid cancer	6.54e-07	9e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HRAS—thyroid cancer	6.51e-07	8.95e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—HRAS—thyroid cancer	6.49e-07	8.92e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—PTEN—thyroid cancer	6.43e-07	8.84e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HRAS—thyroid cancer	6.32e-07	8.69e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—KRAS—thyroid cancer	6.24e-07	8.58e-06	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—AKT1—thyroid cancer	6.15e-07	8.45e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	6.12e-07	8.41e-06	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—AKT1—thyroid cancer	6.06e-07	8.33e-06	CbGpPWpGaD
Crizotinib—JAK2—Disease—AKT1—thyroid cancer	6.04e-07	8.31e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—KRAS—thyroid cancer	6.02e-07	8.28e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—HRAS—thyroid cancer	5.99e-07	8.24e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—CCND1—thyroid cancer	5.9e-07	8.11e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PPARG—thyroid cancer	5.87e-07	8.07e-06	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—AKT1—thyroid cancer	5.75e-07	7.9e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—HRAS—thyroid cancer	5.74e-07	7.9e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—NRAS—thyroid cancer	5.74e-07	7.89e-06	CbGpPWpGaD
Crizotinib—LCK—Immune System—AKT1—thyroid cancer	5.73e-07	7.88e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—RXRA—thyroid cancer	5.73e-07	7.87e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—PTEN—thyroid cancer	5.69e-07	7.82e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—KRAS—thyroid cancer	5.64e-07	7.75e-06	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—AKT1—thyroid cancer	5.58e-07	7.67e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—TP53—thyroid cancer	5.35e-07	7.36e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—PTEN—thyroid cancer	5.34e-07	7.34e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—HRAS—thyroid cancer	5.3e-07	7.29e-06	CbGpPWpGaD
Crizotinib—LCK—Disease—AKT1—thyroid cancer	5.29e-07	7.27e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HRAS—thyroid cancer	5.12e-07	7.04e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—NRAS—thyroid cancer	5.08e-07	6.98e-06	CbGpPWpGaD
Crizotinib—SRC—Immune System—AKT1—thyroid cancer	5.07e-07	6.97e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—TP53—thyroid cancer	5.01e-07	6.89e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—KRAS—thyroid cancer	4.94e-07	6.79e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HRAS—thyroid cancer	4.79e-07	6.59e-06	CbGpPWpGaD
Crizotinib—SRC—Disease—AKT1—thyroid cancer	4.68e-07	6.44e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTGS2—thyroid cancer	4.62e-07	6.35e-06	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—AKT1—thyroid cancer	4.52e-07	6.21e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—TP53—thyroid cancer	4.39e-07	6.03e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—KRAS—thyroid cancer	4.37e-07	6.01e-06	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—AKT1—thyroid cancer	4.23e-07	5.82e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HRAS—thyroid cancer	4.2e-07	5.77e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—PTEN—thyroid cancer	4.03e-07	5.54e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—TP53—thyroid cancer	3.88e-07	5.34e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HRAS—thyroid cancer	3.71e-07	5.11e-06	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—AKT1—thyroid cancer	3.7e-07	5.09e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PPARG—thyroid cancer	3.62e-07	4.97e-06	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—AKT1—thyroid cancer	3.28e-07	4.51e-06	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—AKT1—thyroid cancer	3.08e-07	4.23e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	2.84e-07	3.91e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—PTEN—thyroid cancer	2.48e-07	3.41e-06	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—AKT1—thyroid cancer	2.32e-07	3.19e-06	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—AKT1—thyroid cancer	1.43e-07	1.97e-06	CbGpPWpGaD
